





Delivery address (opens 24/7):

Patient Specimen Reception
 Level 5 Acute Services Building, Royal North Shore Hospital,
 Pacific Highway, St Leonards, NSW 2065

Sample type and volume required:

FFPE Skin biopsy	NOT suitable		
Blood	10ml, EDTA		
Bone marrow	1ml, EDTA		
Body fluid	5ml, in 50ml sterile screw-top conical bottom tube 		
Fresh / frozen tissue	NO saline, culture medium, gauze, cotton wool etc. >1mm ³ <u>naked</u> , in 5ml sterile screw-top conical bottom tube 		
	Required tube: Eppendorf 5.0 mL with screw cap, PCR clean, colorless, cat #0030122321		
FFPE tissue	30 shavings of 5µm in 5ml sterile screw-top conical bottom tube (same as fresh / frozen tissues). Slides and blocks are <u>not</u> accepted.		

Transport instructions:

Blood / marrow / FFPE tissue	room temperature
Body fluid / Fresh tissue	wet ice
Frozen tissue	dry ice

Rejection criteria (clonality analysis):

< 5% lymphoid population in the sample; clotted; non-dedicated specimen; samples in anticoagulant other than EDTA; sample in incorrect tube type (see above); FFPE skin biopsy; FFPE block; slide.

Turn-around time: 4-6 weeks, depending on sample type

Cost (non-MBS):

DNA integrity check (FFPE & compromised samples only)	\$120
IGH + IGK clonality analysis – Diagnostic investigation	\$750
TCR clonality analysis - Diagnostic investigation	\$750
IGH Minimal residual disease detection, per marker	\$1550 *
TCR Minimal residual disease detection, per marker	\$1550 *
Sequence review (within 4 years of test date)	\$440

N.B. FFPE from different blocks are analysed independently, attracting DNA integrity check fee plus assay cost each.

* MBS item #73310 - From 01 November 2023, Measurable residual disease (MRD) testing by next-generation sequencing, performed on bone marrow from a patient diagnosed with acute lymphoblastic leukaemia for the purposes of determining baseline MRD or facilitating the determination of MRD following combination chemotherapy or after salvage therapy, requested by a specialist or consultant physician practising as a haematologist or oncologist. The number of measurable residual disease (MRD) tests per patient, per episode of disease or per relapse is not expected to exceed 12, inclusive of a baseline assessment.

For further enquiries:

Genetics NSW Health Pathology, Royal North Shore Hospital campus
 Dr Linda Lee 02 9926 4370 NSLHD-MolecularGenetics@health.nsw.gov.au